EGFR and lung adenocarcinoma: EGFR-TKIs-challenged therapy for EGFR-mutant lung adenocarcinoma patients who acquired treatment resistance shows only moderate efficacy, and there were few pieces of research focused on the effect of Apatinib on EGFR-TKI resistance patients.